We read with great interest Henderson and colleagues’ paper in your journal (2009;
29:165–169), which reported that aripiprazole reduced olanzapine-induced
overweight/obesity and hyperlipidemia in a 10-week placebo-controlled double-blind
crossover study. This and their previous studies, provide a new way for controlling
olanzapine- and clozapine-induced weight gain/obesity using another atypical
antipsychotic, even without reducing the original olanzapine and clozapine doses,
which is important particularly for treatment of refractory schizophrenia patients.